{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:26:58Z","timestamp":1793917618058,"version":"4.8.0"},"reference-count":285,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer is among the most prevalent malignant tumors of the digestive system worldwide. In recent years, immune checkpoint inhibitors (ICIs) have achieved substantial advances in the treatment of gastric cancer. By blocking the PD-1\/PD-L1 and CTLA-4 signaling pathways, ICIs enhance antitumor immune responses and offer novel therapeutic options for patients. However, their clinical application continues to face significant challenges, including therapeutic resistance, immune-related adverse events, the lack of reliable biomarkers, and an immunosuppressive tumor microenvironment. This narrative review summarizes recent advances in ICIs-based therapies for gastric cancer, provides an in-depth analysis of existing clinical challenges, and highlights key future research directions, including biomarker discovery, development of predictive models, optimization of combination regimens, targeting of resistance mechanisms, modulation of the tumor-associated microbiota, and improved toxicity management. Moving forward, efforts should focus on advancing immunotherapy toward individualized and precision-based approaches to maximize both efficacy and safety, thereby enabling further optimization and breakthroughs in gastric cancer immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1716934","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:28:38Z","timestamp":1772083718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects"],"prefix":"10.3389","volume":"17","author":[{"given":"Penghui","family":"Liu","sequence":"first","affiliation":[{"name":"Lanzhou University Second Hospital, The General Surgery Department","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital, The General Surgery Department","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwu","family":"Guo","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital, The General Surgery Department","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyu Tong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Northeastern University","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital, The General Surgery Department","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Mou","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital, The General Surgery Department","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mao","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital, The General Surgery Department","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5114\/pg.2018.80001","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0421-1","article-title":"Immunotherapy for gastric cancer: A focus on immune checkpoints","volume":"11","author":"Alsina","year":"2016","journal-title":"Target Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s10020-025-01075-y","article-title":"Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives","volume":"31","author":"Luo","year":"2025","journal-title":"Mol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104767","article-title":"The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: A narrative review with biological and clinical aspects","volume":"212","author":"Wekking","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13167-025-00403-w","article-title":"Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management","volume":"16","author":"Baldi","year":"2025","journal-title":"EPMA J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1377690","article-title":"First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01577-4","article-title":"Tumor infiltration of inactive CD8\u2009+\u2009T cells was associated with poor prognosis in Gastric Cancer","volume":"28","author":"Katayama","year":"2025","journal-title":"Gastric Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10120-019-00983-3","article-title":"Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance","volume":"23","author":"Pernot","year":"2020","journal-title":"Gastric Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.685992","article-title":"The immune subtypes and landscape of gastric cancer and to predict based on the whole-slide images using deep learning","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-025-03861-3","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in advanced or metastatic gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"81","author":"Piao","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-023-02083-y","article-title":"Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy","volume":"21","author":"Kiaie","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1592733","article-title":"Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0218","article-title":"DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer","volume":"10","author":"Shi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-021-01475-8","article-title":"The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p","volume":"20","author":"Chen","year":"2021","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02172-0","article-title":"PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma","volume":"26","author":"Lim","year":"2025","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003303","article-title":"Neoadjuvant sintilimab and apatinib combined with perioperative FLOT chemotherapy for locally advanced gastric cancer: A prospective, single-arm, phase II study","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065x.1996.tb00918.x","article-title":"The role of B7-1\/B7-2:CD28\/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response","volume":"153","author":"Boussiotis","year":"1996","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061580","article-title":"Addressing the elephant in the immunotherapy room: effector T-cell priming versus depletion of regulatory T-cells by anti-CTLA-4 therapy","volume":"14","author":"Hong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600792","article-title":"Galectin\u22129 and Tim\u22123 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti\u2212PD\u22121 blockade","volume":"16","author":"Hill","year":"2025","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202301_30906","article-title":"Research progress of immune heckpoint LAG-3 in gastric cancer: a narrative review","volume":"27","author":"Guo","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34296","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis","volume":"152","author":"Liu","year":"2023","journal-title":"Int J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01535-0","article-title":"Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Boku","year":"2024","journal-title":"Gastric Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264","article-title":"randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0093","article-title":"MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"100531","DOI":"10.1016\/j.medj.2024.10.008","article-title":"Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric\/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study","volume":"6","author":"Long","year":"2025","journal-title":"Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638316","article-title":"Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric\/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial","volume":"16","author":"Meng","year":"2025","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1080990","article-title":"Challenges and future of HER2-positive gastric cancer therapy","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166040","article-title":"Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study","volume":"13","author":"Deng","year":"2023","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2020-0737","article-title":"First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811","volume":"17","author":"Chung","year":"2021","journal-title":"Future Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061227","article-title":"HER2 and PD-L1 expression in gastric and gastroesophageal junction cancer: insights for combinatorial targeting approaches","volume":"16","author":"Freitas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-024-02085-w","article-title":"Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"25030","DOI":"10.1038\/s41598-024-76296-y","article-title":"Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study","volume":"14","author":"Cen","year":"2024","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35387","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study","volume":"130","author":"Chung","year":"2024","journal-title":"Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0937","article-title":"The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors","volume":"17","author":"Taylor","year":"2021","journal-title":"Future Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/ol.2020.11905","article-title":"Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress","volume":"20","author":"Song","year":"2020","journal-title":"Oncol Lett"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-73","article-title":"Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study","volume":"14","author":"Xu","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1853","article-title":"Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers","volume":"30","author":"Barrett","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e71065","DOI":"10.1002\/cam4.71065","article-title":"Current advances and future directions for sensitizing gastric cancer to immune checkpoint inhibitors","volume":"14","author":"Li","year":"2025","journal-title":"Cancer Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15057","article-title":"Immune infiltration profiling in gastric cancer and their clinical implications","volume":"112","author":"Ren","year":"2021","journal-title":"Cancer Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228877","article-title":"The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer","volume":"21","author":"Storozynsky","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285343","article-title":"Resistance to immune checkpoint inhibitors in gastric cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/s12916-024-03801-5","article-title":"Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study","volume":"22","author":"Zhang","year":"2024","journal-title":"BMC Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529403","article-title":"Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints","volume":"16","author":"Jing","year":"2025","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-\u03baB in cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01207-3","article-title":"Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy","volume":"24","author":"Li","year":"2021","journal-title":"Gastric Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e007104","DOI":"10.1136\/jitc-2023-007104","article-title":"Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade","volume":"11","author":"Randon","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3892\/or.2024.8847","article-title":"Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review)","volume":"53","author":"Yun","year":"2025","journal-title":"Oncol Rep"},{"key":"B92","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41419-025-07544-w","article-title":"Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application","volume":"16","author":"Pan","year":"2025","journal-title":"Cell Death Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1285049","article-title":"Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers","volume":"15","author":"Reis","year":"2024","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00262-024-03825-z","article-title":"Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors","volume":"73","author":"Malhotra","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B99","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"Mortezaee","year":"2024","journal-title":"Clin Exp Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210164","article-title":"Immune escape and resistance to immunotherapy in mismatch repair deficient tumors","volume":"14","author":"Mestrallet","year":"2023","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01425-7","article-title":"Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers","volume":"125","author":"Baxter","year":"2021","journal-title":"Br J Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203833","article-title":"Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects","volume":"14","author":"Chen","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"key":"B105","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","article-title":"The TIM3\/Gal9 signaling pathway: An emerging target for cancer immunotherapy","volume":"510","author":"Kandel","year":"2021","journal-title":"Cancer Lett"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2016","journal-title":"Oncoimmunology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40364-024-00671-0","article-title":"Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements","volume":"12","author":"Mart\u00ednez-P\u00e9rez","year":"2024","journal-title":"biomark Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41467-020-14290-4","article-title":"Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-\u03b3-signaling mutant cancer cells","volume":"11","author":"Williams","year":"2020","journal-title":"Nat Commun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693609","article-title":"Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","article-title":"New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities","volume":"11","author":"Dai","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1377532","article-title":"Editorial: Spatial immune cell heterogeneity in the tumor microenvironment","volume":"15","author":"Ganguly","year":"2024","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1315283","article-title":"TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells","volume":"15","author":"Cianciotti","year":"2024","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e202451102","DOI":"10.1002\/eji.202451102","article-title":"Metabolic dialogue shapes immune response in the tumor microenvironment","volume":"55","author":"Gao","year":"2025","journal-title":"Eur J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409238","article-title":"Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function","volume":"15","author":"Schuurmans","year":"2024","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915094","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell Biosci"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e006500","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991433","article-title":"Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2024.2798","article-title":"Factors associated with immune-related severe adverse events (Review)","volume":"22","author":"Su","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"30983","DOI":"10.1038\/s41598-024-82105-3","article-title":"Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879900","article-title":"Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: A multi-center study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e2340695","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i8.1002","article-title":"Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors","volume":"15","author":"Guo","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106364","article-title":"Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients","volume":"140","author":"Hernando-Calvo","year":"2023","journal-title":"Oral Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061225","article-title":"Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors","volume":"16","author":"Ponvilawan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae067","article-title":"The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors","volume":"54","author":"Fukushima","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1599908","article-title":"Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01523-4","article-title":"Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair","volume":"27","author":"Ooki","year":"2024","journal-title":"Gastric Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00783-5","article-title":"Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study","volume":"24","author":"Wang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405485","article-title":"PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET","volume":"15","author":"Ibrahim","year":"2024","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2085","article-title":"Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5816","article-title":"Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: A meta-analysis including low PD-L1 subgroups","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26604","article-title":"Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression","volume":"124","author":"Pereira","year":"2021","journal-title":"J Surg Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2906-9","article-title":"Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches","volume":"75","author":"Ratti","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"B149","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"21743","DOI":"10.1038\/s41598-023-48157-7","article-title":"Low incidence of microsatellite instability in gastric cancers and its association with the clinicopathological characteristics: a comparative study","volume":"13","author":"Talari","year":"2023","journal-title":"Sci Rep"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02518-y","article-title":"Incidence and molecular characteristics of deficient mismatch repair conditions across nine different tumors and identification of germline variants involved in Lynch-like syndrome","volume":"29","author":"Ito","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611719","article-title":"Microsatellite instability and mismatch repair protein deficiency: equal predictive markers","volume":"30","author":"N\u00e1dorv\u00e1ri","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14103-0","article-title":"Heterogeneity and adjuvant therapeutic approaches in MSI-H\/dMMR resectable gastric cancer: emerging trends in immunotherapy","volume":"30","author":"Wu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1136437","article-title":"PD-1 inhibitors-based second-line therapy for metastatic gastric cancer","volume":"14","author":"Gou","year":"2023","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00292-023-01208-2","article-title":"Testing for deficient mismatch repair and microsatellite instability: A focused update","volume":"44","author":"R\u00fcschoff","year":"2023","journal-title":"Pathologie (Heidelb)"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706652","article-title":"Prognostic role of tumor mutational burden in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2023.23.e29","article-title":"The optimal tumor mutational burden cutoff value as a novel marker for predicting the efficacy of programmed cell death-1 checkpoint inhibitors in advanced gastric cancer","volume":"23","author":"Jang","year":"2023","journal-title":"J Gastric Cancer"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0824","article-title":"Of context, quality, and complexity: fine-combing tumor mutational burden in immunotherapy-treated cancers","volume":"31","author":"Niknafs","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e0239966","DOI":"10.1371\/journal.pone.0239966","article-title":"Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA","volume":"15","author":"Sasaki","year":"2020","journal-title":"PLoS One"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.751407","article-title":"Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.medj.2024.07.006","article-title":"Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial","volume":"5","author":"Shi","year":"2024","journal-title":"Med"},{"key":"B163","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40164-023-00442-x","article-title":"Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01621-x","article-title":"Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer","volume":"28","author":"He","year":"2025","journal-title":"Gastric Cancer"},{"key":"B166","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.1038\/s41598-023-33128-9","article-title":"Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy","volume":"13","author":"Shin","year":"2023","journal-title":"Sci Rep"},{"key":"B167","doi-asserted-by":"publisher","first-page":"S1471","DOI":"10.1016\/j.molmed.2025.05.007","article-title":"Gastric cancer: from biomarkers to functional precision medicine","volume":"23","author":"Albrecht","year":"2025","journal-title":"Trends Mol Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002312","article-title":"Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control","volume":"6","author":"Marimuthu","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1506849","article-title":"Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight","volume":"14","author":"Sun","year":"2024","journal-title":"Front Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512509","article-title":"The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200773","article-title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party","volume":"32","author":"Lu","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1186\/s12967-024-05867-4","article-title":"Association of PD-1\u2009+\u2009Treg\/PD-1\u2009+\u2009CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1002\/ctm2.1386","article-title":"Tumour-associated macrophages in gastric cancer: From function and mechanism to application","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.7150\/jca.49707","article-title":"Cancer-associated fibroblasts in gastric cancer affect Malignant progression via the CXCL12-CXCR4 axis","volume":"12","author":"Qin","year":"2021","journal-title":"J Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v129.10710","article-title":"Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential","volume":"129","author":"Milosevic","year":"2024","journal-title":"Ups J Med Sci"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1194123","article-title":"Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.11.002","article-title":"Reprogramming endothelial cells to empower cancer immunotherapy","volume":"30","author":"Cleveland","year":"2024","journal-title":"Trends Mol Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1135456","article-title":"Cancer immune exclusion: breaking the barricade for a successful immunotherapy","volume":"13","author":"Bruni","year":"2023","journal-title":"Front Oncol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082273","article-title":"Current progress on predictive biomarkers for response to immune checkpoint inhibitors in gastric cancer: how to maximize the immunotherapeutic benefit","volume":"15","author":"Liu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712760","article-title":"The impact of mismatch repair status on prognosis of patients with gastric cancer: A multicenter analysis","volume":"11","author":"Guan","year":"2021","journal-title":"Front Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04954-1","article-title":"LAG3 in gastric cancer: it\u2019s complicated","volume":"149","author":"Ulase","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i12.2212","article-title":"Prognostic value of T cell immunoglobulin and mucin-domain containing-3 expression in upper gastrointestinal tract tumors: A meta-analysis","volume":"15","author":"Yan","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"e1578","DOI":"10.1002\/ctm2.1578","article-title":"Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer","volume":"14","author":"Cao","year":"2024","journal-title":"Clin Transl Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0436","article-title":"PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer","volume":"21","author":"Qiu","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102510","article-title":"Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis","volume":"49","author":"Cao","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00432-024-05672-y","article-title":"Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies","volume":"150","author":"Peng","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i4.478","article-title":"Tumor infiltrating lymphocytes in gastric cancer: Unraveling complex interactions for precision medicine","volume":"15","author":"Kapoor","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1056144","article-title":"A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer","volume":"13","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3390\/biom14101202","article-title":"Targeting lactate: an emerging strategy for macrophage regulation in chronic inflammation and cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Biomolecules"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B195","doi-asserted-by":"publisher","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00796-z","article-title":"TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective","volume":"23","author":"Nixon","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010006","article-title":"Vascular endothelial growth factor (VEGF) family and the immune system: activators or inhibitors","volume":"13","author":"Failla","year":"2024","journal-title":"Biomedicines"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B201","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1471273","article-title":"Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205105","article-title":"The role of ctDNA in gastric cancer","volume":"14","author":"Mencel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B205","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s43856-025-00867-x","article-title":"Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma","volume":"5","author":"Tougeron","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1595124","article-title":"Recent progress in the study of exosomes in the gastric cancer immune microenvironment","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12935-025-03806-x","article-title":"Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects","volume":"25","author":"Lu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1560583","article-title":"Exosomes and their cargo proteins in diagnosis, process and treatment of gastric cancer","volume":"13","author":"Lu","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3892\/ol.2024.14285","article-title":"Applications of single-cell omics and spatial transcriptomics technologies in gastric cancer (Review)","volume":"27","author":"Ren","year":"2024","journal-title":"Oncol Lett"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/s41467-023-38360-5","article-title":"Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer","volume":"14","author":"Sun","year":"2023","journal-title":"Nat Commun"},{"key":"B211","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41698-025-00967-w","article-title":"Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer","volume":"9","author":"Qiu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol Cancer"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2493539","article-title":"Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts","volume":"21","author":"Dong","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2312628","article-title":"Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition","volume":"13","author":"Li","year":"2024","journal-title":"Oncoimmunology"},{"key":"B215","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-024-00534-9","article-title":"A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking","volume":"8","author":"Ligero","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101146","article-title":"Non-invasive tumor microenvironment evaluation and treatment response prediction in gastric cancer using deep learning radiomics","volume":"4","author":"Jiang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-022-03709-9","article-title":"Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study","volume":"48","author":"Gu","year":"2023","journal-title":"Abdom Radiol (NY)"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.982983","article-title":"Tumor response assessment on imaging following immunotherapy","volume":"12","author":"Berz","year":"2022","journal-title":"Front Oncol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41698-024-00656-0","article-title":"Radiology and multi-scale data integration for precision oncology","volume":"8","author":"Paverd","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15050166","article-title":"Beyond biomarkers: machine learning-driven multiomics for personalized medicine in gastric cancer","volume":"15","author":"Ma","year":"2025","journal-title":"J Pers Med"},{"key":"B221","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c04856","article-title":"Construction of an immunophenoscore-related signature for evaluating prognosis and immunotherapy sensitivity in ovarian cancer","volume":"8","author":"Jiang","year":"2023","journal-title":"ACS Omega"},{"key":"B223","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-025-00855-3","article-title":"An interpretable machine learning model based on computed tomography radiomics for predicting programmed death ligand 1 expression status in gastric cancer","volume":"25","author":"Dai","year":"2025","journal-title":"Cancer Imaging"},{"key":"B224","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41467-022-32816-w","article-title":"Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Nat Commun"},{"key":"B225","doi-asserted-by":"publisher","first-page":"e61220","DOI":"10.7759\/cureus.61220","article-title":"Artificial intelligence and machine learning in predicting the response to immunotherapy in non-small cell lung carcinoma: A systematic review","volume":"16","author":"Sinha","year":"2024","journal-title":"Cureus"},{"key":"B226","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12880-024-01380-8","article-title":"CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Med Imaging"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15050543","article-title":"Predicting PD-L1 in lung adenocarcinoma using 18F-FDG PET\/CT radiomic features","volume":"15","author":"Zhang","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2023.100511","article-title":"Delta-radiomics in cancer immunotherapy response prediction: A systematic review","volume":"11","author":"Abbas","year":"2023","journal-title":"Eur J Radiol Open"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0603-3","article-title":"Reporting guidelines for clinical trials evaluating artificial intelligence interventions are needed","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"B230","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1572195","article-title":"Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216167","article-title":"Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers","volume":"562","author":"Shi","year":"2023","journal-title":"Cancer Lett"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.109515","article-title":"Radiotherapy elicits immunogenic cell death and metabolic shifts in the tumor microenvironment: implications for immunotherapy","volume":"22","author":"Hang","year":"2025","journal-title":"Int J Med Sci"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070473","article-title":"Combination of immunotherapy and radiation therapy in gastrointestinal cancers: an appraisal of the current literature and ongoing research","volume":"30","author":"Kumar","year":"2023","journal-title":"Curr Oncol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"e150735","DOI":"10.1172\/jci.insight.150735","article-title":"VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment","volume":"6","author":"Zhang","year":"2021","journal-title":"JCI Insight"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B240","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-024-01595-w","article-title":"Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B241","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00243","article-title":"Antibody-drug conjugates combinations in cancer treatment","volume":"5","author":"Pretelli","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1211947","article-title":"Antibody-drug conjugates: the clinical development in gastric cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Oncol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtumed.2022.06.013","article-title":"Premarital mental health screening among the Saudi population","volume":"18","author":"Alhusseini","year":"2022","journal-title":"J Taibah Univ Med Sci"},{"key":"B249","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116036","article-title":"Cediranib enhances the transcription of MHC-I by upregulating IRF-1","volume":"221","author":"Zhang","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1325615","article-title":"Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications","volume":"14","author":"Yin","year":"2024","journal-title":"Front Immunol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol Cancer"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","article-title":"Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer","volume":"187","author":"Jia","year":"2024","journal-title":"Cell"},{"key":"B255","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"key":"B257","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp Mol Med"},{"key":"B259","doi-asserted-by":"publisher","first-page":"e006287","DOI":"10.1136\/jitc-2022-006287","article-title":"Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell Malignancies","volume":"11","author":"Lopez","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837230","article-title":"Adenosine-A2A receptor pathway in cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108188","article-title":"Metabolic predictors of response to immune checkpoint blockade therapy","volume":"26","author":"Shorer","year":"2023","journal-title":"iScience"},{"key":"B263","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol Ther"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103061","article-title":"Engineering bacteria for cancer immunotherapy","volume":"85","author":"Zalatan","year":"2024","journal-title":"Curr Opin Biotechnol"},{"key":"B265","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-025-06376-8","article-title":"Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"B266","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41591-022-01779-2","article-title":"Targeting the gut and tumor microbiota in cancer","volume":"28","author":"Park","year":"2022","journal-title":"Nat Med"},{"key":"B267","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323426","article-title":"Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade","volume":"71","author":"Si","year":"2022","journal-title":"Gut"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330291","article-title":"Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells","volume":"72","author":"Kang","year":"2023","journal-title":"Gut"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01326-2","article-title":"The gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut microbiota in cancer immune response and immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"B272","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101478","article-title":"Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy","volume":"5","author":"Kang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00908-9","article-title":"Exploiting bacteria for cancer immunotherapy","volume":"21","author":"Kwon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1240","article-title":"Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events","volume":"28","author":"Smithy","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.89376","article-title":"Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers","volume":"20","author":"Miao","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B277","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41598-023-48546-y","article-title":"Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020302","article-title":"Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma","volume":"14","author":"W\u00f6lffer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1016\/j.pccm.2023.08.002","article-title":"Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects","volume":"1","author":"Miao","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03798-6","article-title":"The role of tumor types in immune-related adverse events","volume":"27","author":"Xu","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B282","doi-asserted-by":"publisher","first-page":"e2122998","DOI":"10.1001\/jamanetworkopen.2021.22998","article-title":"Evaluation of technology-enabled monitoring of patient-reported outcomes to detect and treat toxic effects linked to immune checkpoint inhibitors","volume":"4","author":"Msaouel","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B283","doi-asserted-by":"publisher","first-page":"e073724","DOI":"10.1136\/bmjopen-2023-073724","article-title":"Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study","volume":"13","author":"Hirata","year":"2023","journal-title":"BMJ Open"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocaf074","article-title":"Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning","volume":"32","author":"Yeghaian","year":"2025","journal-title":"J Am Med Inform Assoc"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00408-3","article-title":"Harnessing multimodal data integration to advance precision oncology","volume":"22","author":"Boehm","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1716934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:28:40Z","timestamp":1772083720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1716934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":285,"alternative-id":["10.3389\/fimmu.2026.1716934"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1716934","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1716934"}}